Premium
Enhancement of angiogenin inhibition by polyphenol‐capped gold nanoparticles
Author(s) -
Panda Atashi,
Karhadkar Siddhant,
Acharya Bidisha,
Banerjee Anwesha,
De Soumya,
Dasgupta Swagata
Publication year - 2021
Publication title -
biopolymers
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.556
H-Index - 125
eISSN - 1097-0282
pISSN - 0006-3525
DOI - 10.1002/bip.23429
Subject(s) - angiogenin , chemistry , polyphenol , colloidal gold , angiogenesis , gtp' , biochemistry , chorioallantoic membrane , biophysics , in vitro , nanoparticle , pharmacology , nanotechnology , enzyme , antioxidant , cancer research , medicine , materials science , biology
Angiogenin (Ang), is a ribonucleolytic protein that is associated with angiogenesis, the formation of blood vessels. The involvement of Ang in vascularisation makes it a potential target for the identification of compounds that have the potential to inhibit the process. The compounds may be assessed for their ability to inhibit the ribonucleolytic activity of the protein and subsequently blood vessel formation, a crucial requirement for tumor formation. We report an inhibition of the ribonucleolytic activity of Ang with the gallate containing green tea polyphenols, ECG and EGCG that exhibits an increased efficacy upon forming polyphenol‐capped gold nanoparticles (ECG‐AuNPs and EGCG‐AuNPs). The extent of inhibition was confirmed using an agarose gel‐based assay followed by fluorescence titration studies that indicated a hundred fold stronger binding of polyphenol‐capped gold nanoparticles (GTP‐AuNPs) compared to the bare polyphenols. Interestingly, we found a change in the mode of inhibition from a noncompetitive type to a competitive mode of inhibition in case of the GTP‐AuNPs, which is in agreement with the ' n ' values obtained from the fluorescence quenching studies. The effect on angiogenesis has also been assessed by the chorioallantoic membrane (CAM) assay. We find an increase in the inhibition potency of GTP‐AuNPs that could find applications in the development of anti‐angiogenic compounds.